Urokinase plasminogen activator receptor (uPAR) targeted nuclear imaging and radionuclide therapy

Theranostics

Volumn 3, Issue 7, 2013, Pages 507-515

  Li, Dan ^a,b   Liu, Shuanglong ^a   Shan, Hong ^b   Conti, Peter ^a   Li, Zibo ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

PET; Radionuclide therapy; SPECT; uPAR

Indexed keywords

1,4,7 TRIAZACYCLONONANE1,4,7 TRIACETIC ACID; BINDING PEPTIDE AE105 BI 213; BINDING PEPTIDE AE105 GA 68; BINDING PEPTIDE AE105 TETRAXETAN CU 64; BINDING PEPTIDE AE105 TETRAXETAN LU 177; BINDING PEPTIDE AE105 TETRAXETAN NH2 CU 64; BINDING PEPTIDE AE105 TETRAXETAN NH2 LU 177; BINDING PEPTIDE AE120 TETRAXETAN IN 111; BISMUTH 213; CARBON 11; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; UROKINASE RECEPTOR ANTIBODY I 125;

BINDING AFFINITY; BREAST CANCER; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER SCREENING; DRUG BIOAVAILABILITY; DRUG MONITORING; DRUG RESPONSE; DRUG STRUCTURE; HUMAN; IC 50; IMAGE ANALYSIS; LIGAND BINDING; MOLECULAR IMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RADIATION DOSE; REVIEW; TUMOR VOLUME;

EID: 84883151738     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.5557     Document Type: Review

References (55)

1. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F and Dano K. Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 1991; 266: 1926-1933.
2. Smith HW and Marshall CJ. Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 2010; 11: 23-36.
3. D'Alessio S and Blasi F. The urokinase receptor as an entertainer of signal transduction. Front Biosci 2009; 14: 4575-4587.
4. Dass K, Ahmad A, Azmi AS, Sarkar SH and Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev 2008; 34: 122-136.
5. Ge Y and Elghetany MT. Urokinase plasminogen activator receptor (CD87): something old, something new. Lab Hematol 2003; 9: 67-71.
6. de Bock CE and Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev 2004; 24: 13-39.
7. Wang Y. The role and regulation of urokinase-type plasminogen activator receptor gene expression in cancer invasion and metastasis. Med Res Rev 2001; 21: 146-170.
8. Goodson RJ, Doyle MV, Kaufman SE and Rosenberg S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci U S A 1994; 91: 7129-7133.
9. Ploug M, Ostergaard S, Gardsvoll H, Kovalski K, Holst-Hansen C, Holm A, Ossowski L and Dano K. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry 2001; 40: 12157-12168.
10. Kriegbaum MC, Persson M, Haldager L, Alpizar-Alpizar W, Jacobsen B, Gardsvoll H, Kjaer A and Ploug M. Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes. Curr Drug Targets 2011 Nov;12(12):1711-28.
11. Li ZB, Niu G, Wang H, He L, Yang L, Ploug M and Chen X. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clin Cancer Res 2008; 14: 4758-4766.
12. Persson M, Madsen J, Ostergaard S, Jensen MM, Jorgensen JT, Juhl K, Lehmann C, Ploug M and Kjaer A. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med 2012; 53: 138-145.
13. Persson M, Madsen J, Ostergaard S, Ploug M and Kjaer A. 68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol 2012; 39: 560-569.
14. Liu D, Overbey D, Watkinson L and Giblin MF. Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR). Bioconjug Chem 2009; 20: 888-894.
15. Knor S, Sato S, Huber T, Morgenstern A, Bruchertseifer F, Schmitt M, Kessler H, Senekowitsch-Schmidtke R, Magdolen V and Seidl C. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging 2008; 35: 53-64.
16. Persson M, Rasmussen P, Madsen J, Ploug M and Kjaer A. New peptide receptor radionuclide therapy of invasive cancer cells: in vivo studies using (177)Lu-DOTA-AE105 targeting uPAR in human colorectal cancer xenografts. Nucl Med Biol 2012; 39: 962-969.
17. Lin L, Gardsvoll H, Huai Q, Huang M and Ploug M. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem 2010; 285: 10982-10992.
18. Appella E, Robinson EA, Ullrich SJ, Stoppelli MP, Corti A, Cassani G and Blasi F. The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases. J Biol Chem 1987; 262: 4437-4440.
19. Appella E and Blasi F. The growth factor module of urokinase is the binding sequence for its receptor. Ann N Y Acad Sci 1987; 511: 192-195.
20. Quax PH, Pedersen N, Masucci MT, Weening-Verhoeff EJ, Dano K, Verheijen JH and Blasi F. Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul 1991; 2: 793-803.
21. Li H, Soria C, Griscelli F, Opolon P, Soria J, Yeh P, Legrand C, Vannier JP, Belin D, Perricaudet M and Lu H. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway. Hum Gene Ther 2005; 16: 1157-1167.
22. Yang L, Peng XH, Wang YA, Wang X, Cao Z, Ni C, Karna P, Zhang X, Wood WC, Gao X, Nie S and Mao H. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res 2009; 15: 4722-4732.
23. Yang L, Mao H, Cao Z, Wang YA, Peng X, Wang X, Sajja HK, Wang L, Duan H, Ni C, Staley CA, Wood WC, Gao X and Nie S. Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology 2009; 136: 1514-1525.
24. Abdalla MO, Karna P, Sajja HK, Mao H, Yates C, Turner T and Aneja R. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J Control Release 2011; 149: 314-322.
25. Burgle M, Koppitz M, Riemer C, Kessler H, Konig B, Weidle UH, Kellermann J, Lottspeich F, Graeff H, Schmitt M, Goretzki L, Reuning U, Wilhelm O and Magdolen V. Inhibition of the interaction of urokinase-type plasminogen activator (uPA) with its receptor (uPAR) by synthetic peptides. Biol Chem 1997; 378: 231-237.
26. Magdolen V, Burgle M, de Prada NA, Schmiedeberg N, Riemer C, Schroeck F, Kellermann J, Degitz K, Wilhelm OG, Schmitt M and Kessler H. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87). Biol Chem 2001; 382: 1197-1205.
27. Schmiedeberg N, Schmitt M, Rolz C, Truffault V, Sukopp M, Burgle M, Wilhelm OG, Schmalix W, Magdolen V and Kessler H. Synthesis, solution structure, and biological evaluation of urokinase type plasminogen activator (uPA)-derived receptor binding domain mimetics. J Med Chem 2002; 45: 4984-4994.
28. Armstrong AF, Lemon JA, Czorny SK, Singh G and Valliant JF. Evaluation of single amino acid chelate derivatives and regioselective radiolabelling of a cyclic peptide for the urokinase plasminogen activator receptor. Nucl Med Biol 2009; 36: 907-917.
29. Fischer K, Lutz V, Wilhelm O, Schmitt M, Graeff H, Heiss P, Nishiguchi T, Harbeck N, Kessler H, Luther T, Magdolen V and Reuning U. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function. FEBS Lett 1998; 438: 101-105.
30. Deng G, Royle G, Wang S, Crain K and Loskutoff DJ. Structural and functional analysis of the plasminogen activator inhibitor-1 binding motif in the somatomedin B domain of vitronectin. J Biol Chem 1996; 271: 12716-12723.
31. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S and Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380-32388.
32. Lu H, Yeh P, Guitton JD, Mabilat C, Desanlis F, Maury I, Legrand Y, Soria J and Soria C. Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin. FEBS Lett 1994; 356: 56-59.
33. Hu XW, Duan HF, Gao LH, Pan SY, Li YM, Xi Y, Zhao SR, Yin L, Li JF, Chen HP and Wu CT. Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. Cancer Biol Ther 2008; 7: 651-659.
34. Luther T, Magdolen V, Albrecht S, Kasper M, Riemer C, Kessler H, Graeff H, Muller M and Schmitt M. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol 1997; 150: 1231-1244.
35. Bauer TW, Liu W, Fan F, Camp ER, Yang A, Somcio RJ, Bucana CD, Callahan J, Parry GC, Evans DB, Boyd DD, Mazar AP and Ellis LM. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 2005; 65: 7775-7781.
36. Duriseti S, Goetz DH, Hostetter DR, LeBeau AM, Wei Y and Craik CS. Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration. J Biol Chem 2010; 285: 26878-26888.
37. Rabbani SA and Gladu J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res 2002; 62: 2390-2397.
38. Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP and Lengyel E. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res 2011; 17: 459-471.
39. Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, Kerfoot CA and Mazar AP. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo. Neoplasia 2010; 12: 778-788.
40. Dullin C, Zientkowska M, Napp J, Missbach-Guentner J, Krell HW, Muller F, Grabbe E, Tietze LF and Alves F. Semiautomatic landmark-based two-dimensional-three-dimensional image fusion in living mice: correlation of near-infrared fluorescence imaging of Cy5.5-labeled antibodies with flat-panel volume computed tomography. Mol Imaging 2009; 8: 2-14.
41. van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, Sarantopoulos A, de Jong JS, Arts HJ, van der Zee AG, Bart J, Low PS and Ntziachristos V. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med 2011; 17: 1315-1319.
42. Rosenberg J SK, Martin EJ. US19985747458. 1998.
43. Bauer S ER, Fertig G, Friebe W, Koerner M, Krell H. WO 04076444. 2004.
44. di Domenico R DCG, König B, Zimmermann G. WO 999906393. 1999.
45. König B WU, Krell H, Kilpert C, Knipp B. WO0979731645. 1997.
46. Behrendt N, Ronne E and Dano K. Binding of the urokinase-type plasminogen activator to its cell surface receptor is inhibited by low doses of suramin. J Biol Chem 1993; 268: 5985-5989.
47. Blood CH NB, Smith EM. US20016228985. 2001.
48. Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P and Reiser J. Modification of kidney barrier function by the urokinase receptor. Nat Med 2008; 14: 55-63.
49. Solberg H, Ploug M, Hoyer-Hansen G, Nielsen BS and Lund LR. The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem 2001; 49: 237-246.
50. Jaggi JS, Seshan SV, McDevitt MR, Sgouros G, Hyjek E and Scheinberg DA. Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys 2006; 64: 1503-1512.
51. Kakizaki T, Yokoyama Y, Natsuhori M, Yamada N, Hashimoto M, Sato K, Ito N and Daniel GB. Quantitative analysis of the effect of probenecid on pharmacokinetics of 99mTc-mercaptoacetyltriglycine in dogs. J Vet Pharmacol Ther 2005; 28: 559-564.
52. Vegt E, Wetzels JF, Russel FG, Masereeuw R, Boerman OC, van Eerd JE, Corstens FH and Oyen WJ. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 2006; 47: 432-436.
53. Engelholm LH and Behrendt N. Differential binding of urokinase and peptide antagonists to the urokinase receptor: evidence from characterization of the receptor in four primate species. Biol Chem 2001; 382: 435-442.
54. Mazar AP. The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer. Anticancer Drugs 2001; 12: 387-400.
55. Mazar AP, Henkin J and Goldfarb RH. The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis. Angiogenesis 1999; 3: 15-32.